# US 2013/0252837 A1 · Method for measuring resistance or sensitivity to docetaxel

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252837 A1
- Document ID: US20130252837A1
- Status: Published application
- Kind: A1
- Application number: 13/833,367
- Filed: 2013-03-15
- Published: 2013-09-26
- Earliest claimed: 2004-12-08
- Assignees: Sanofi US
- Inventors: Dorre GRUENEBERG; Xi HUANG; Sridaran NATESAN; Paul AUGUST
- Web page: https://patentgrep.com/patent/US20130252837A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/575: for cancer
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to novel and useful methods that predict or monitor a patient's response to a molecule of the taxoid family by measuring the increase or decrease of specific genetic markers as compared to controls. The present invention also provides kits that predict of monitor patient's response to a molecule of the taxoid family by measuring nucleic acid or protein levels of particular genetic markers and comparing their levels to controls or reference markers.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A method of determining the sensitivity or resistance of a cancer cell to treatment using a molecule of the taxoid family, the method comprising the steps of:
contacting a portion of the cancer cell with a ligand having specificity for a genetic marker;
calculating a test level of the genetic marker based on the contacting step;
comparing the calculated test level of the genetic marker to a reference level;
determining the sensitivity or resistance of the cancer cell to treatment using a molecule of the taxoid family when the calculated test level of the genetic marker is lower than the reference level.

### Claim 33 (depends on 32)

The method of claim 32, further comprising calculating the reference level, the calculating step comprising:
contacting a portion of a control sample with a ligand having specificity for the genetic marker; and
calculating the reference level based on the contacting step.

### Claim 34 (depends on 32)

The method of claim 32, further comprising calculating the reference level, the calculating step comprising:
contacting a portion of the cancer cell with a ligand having specificity for a reference genetic marker; and
calculating the reference level based on the contacting step.

### Claim 35 (depends on 32)

The method of claim 32, further comprising:
determining the cancer cell has increased resistance to treatment using a molecule of the taxoid family, wherein the genetic marker is BubR1, Mad2, Mps1, GEFT, or BUB1

### Claim 36 (depends on 32)

The method of claim 32, further comprising:
determining the cancer cell has increased sensitivity to treatment using a molecule of the taxoid family, wherein the genetic marker is P21, Pim-1, GBP-1, TACC3, or STK11.

### Claim 37 (depends on 32)

The method of claim 32, wherein the cancer cell is a human cancer cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein the human cancer cell is isolated from a subject or sample.

### Claim 39 (depends on 35)

A method for identifying a subject or tumor with increased resistance to treatment using a molecule of the taxoid family, the method comprising the steps of:
isolating a cancer cell from a biological sample from the subject or tumor;
determining the isolated cancer cell has increased resistance to a molecule of the taxoid family according to the method of claim 35; and
identifying the subject or tumor with increased resistance to treatment using a molecule of the taxoid family.

### Claim 40 (depends on 36)

A method for identifying a subject or tumor with increased sensitivity to treatment using a molecule of the taxoid family, the method comprising the steps of:
isolating a cancer cell from a biological sample from the subject or tumor;
determining the isolated cancer cell has increased sensitivity to a molecule of the taxoid family according to the method of claim 36; and
identifying the subject or tumor with increased sensitivity to treatment using a molecule of the taxoid family.

### Claim 41 (depends on 39)

A method of selecting a treatment for a subject or tumor, the method comprising the steps of:
identifying the subject or tumor with increased resistance to treatment using a molecule of the taxoid family according to the method of claim 39; and
avoiding the selection of a treatment using a molecule of the taxoid family.

### Claim 42 (depends on 40)

A method of selecting a treatment for a subject or tumor, the method comprising the steps of:
identifying the subject or tumor with increased sensitivity to treatment using a molecule of the taxoid family according to the method of claim 40; and
selecting a treatment using a molecule of the taxoid family.

### Claim 43 (depends on 32)

The method of claim 32, wherein the ligand comprises an antibody.

### Claim 44 (depends on 32)

The method of claim 32, wherein the ligand comprises a nucleic acid.

### Claim 45 (depends on 32)

The method of claim 32, wherein the molecule of the taxoid family is paclitaxel, docetaxel, XRP9881, or XRP6258.

### Claim 46 (depends on 32)

The method of claim 32, wherein the level of genetic marker is measured by mRNA, DNA, or protein.

### Claim 47 (depends on 46)

The method of claim 46, wherein the mRNA is measured by in situ hybridization, reverse-transcriptase polymerase chain reaction, nucleic acid hybridization, electrophoresis, Northern blotting, or mass spectrometry.

### Claim 48 (depends on 46)

The method of claim 46 wherein the DNA is measured by quantitative polymerase chain reaction, genomic DNA-chips, in situ hybridization, electrophoresis, Southern blotting, or mass spectrometry.

### Claim 49 (depends on 46)

The method of claim 46 wherein the protein is measured by immunoassay, Western blots, ELISA, or mass spectrometry.

### Claim 50

A system for providing the sensitivity or resistance of a subject or tumor to treatment using a molecule of the taxoid family, the system comprising:
an analysis unit configured to contact, in vitro, a portion of a sample from a subject or tumor with a first ligand having specificity for a genetic marker;
a computing device having a processor and being in operable communication with said analysis unit; and
a non-transient machine readable media including a plurality of instructions executable by the processor; the instructions, when executed calculate a level of genetic marker, and provide the sensitivity or resistance of the subject or tumor to treatment using a molecule of the taxoid family when the calculated test level of the genetic marker is lower than a reference level of the genetic marker.

### Claim 51 (depends on 50)

The system of claim 50, further comprising:
determining the cancer cell has increased resistance to treatment using a molecule of the taxoid family, wherein the genetic marker is BubR1, Mad2, Mps1, GEFT, or BUB1.

### Claim 52 (depends on 50)

The system of claim 50, further comprising:
determining the cancer cell has increased sensitivity to treatment using a molecule of the taxoid family, wherein the genetic marker is P21, Pim-1, GBP-1, TACC3, or STK11.
